comprehensive -WSS

comprehensive

author：knowledge 2025-09-29 20:00:28 - browse：1966

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Let's speed up science by embracing open access publishing

explore

WSS

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

How to increase colonoscopy rates? Looks like an AI can help

Readout Newsletter: BridgeBio, Akero, and human embryo models

BMI, flaws aside, is found to be useful estimate of body fat in youth

NIH documents show early flaws of $1.6 billion long Covid program

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Ultragenyx gene therapy for rare liver ailment succeeds in late

In age of alternative facts, a scholarly course on calling out crap

First over

The high cost of giving birth even with insurance

Readout Newsletter: BridgeBio, Akero, and human embryo models

DIEP, the 'gold standard' of breast reconstruction, is under threat

Longer MASH drug regimen improved liver, Akero study finds

Alkermes shareholders re

ASCO: Palliative care found as helpful given virtually as in person

hotspot

Medicare drug price negotiation hearing pits pharma v Biden admin

State of the Union pitch: Bigger Medicare drug price negotiations

Ionis drug prevents swelling attacks due to hereditary angioedema

Ionis drug prevents swelling attacks due to hereditary angioedema

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Microsoft's Peter Lee: Generative AI could help doctors be more human

hotspot

Wikipedia

explore

focus